Morphofunctional Changes of the Gastric Mucosa in Diffuse Liver Diseases
Keywords:
diffuse liver diseases, gastric mucosa, Helicobacter pylori, atrophic gastritis, Gastropanel, liver cirrhosis, steatosis, hepatitis, morphofunctional changes, endoscopy, gastric carcinogenesisAbstract
This article investigates the morphofunctional changes of the gastric mucosa in patients with diffuse liver diseases. During the study, the prevalence of Helicobacter pylori infection, atrophic gastritis, and functional disorders of the gastric mucosa was analyzed in patients with steatosis, hepatitis, and liver cirrhosis. The condition of the gastric mucosa was evaluated using Gastropanel testing and endoscopic examination methods. According to the study results, Helicobacter pylori infection was identified in 89.0% of patients. HP-associated gastritis was more commonly observed in men, whereas corpus and antral atrophy predominated among women. In addition, patients with liver cirrhosis demonstrated more pronounced morphofunctional changes of the gastric mucosa. The findings indicate that comprehensive evaluation of the gastric mucosa in patients with diffuse liver diseases is of great clinical importance for the early detection of high-risk atrophic processes and the timely implementation of preventive measures.
References
[1] Biohit Healthcare, Gastropanel Examination and Clinical Interpretation Manual. Helsinki, Finland: Biohit Healthcare, 2021.
[2] P. Correa, “Human gastric carcinogenesis: A multistep and multifactorial process,” Cancer Research, vol. 52, no. 24, pp. 6735–6740, 1992.
[3] M. Dinis-Ribeiro, “Management of precancerous conditions and lesions in the stomach,” Endoscopy, vol. 44, no. 1, pp. 74–94, 2012.
[4] R. H. Hunt, S. D. Xiao, F. Megraud, et al., “Helicobacter pylori in developing countries: World Gastroenterology Organisation Global Guideline,” Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 3, pp. 299–304, 2011.
[5] International Agency for Research on Cancer, GLOBOCAN 2022: Stomach Cancer Fact Sheet. Lyon, France: IARC, 2022.
[6] K. Kimura and T. Takemoto, “An endoscopic recognition of the atrophic border and its significance in chronic gastritis,” Endoscopy, vol. 1, pp. 87–97, 1969.
[7] P. Malfertheiner, F. Megraud, T. Rokkas, et al., “Management of Helicobacter pylori infection: The Maastricht VI/Florence Consensus Report,” Gut, vol. 71, no. 9, pp. 1724–1762, 2022.
[8] P. Pimentel-Nunes, D. Libanio, R. Marcos-Pinto, et al., “Management of epithelial precancerous conditions and lesions in the stomach — MAPS II,” Endoscopy, vol. 51, no. 4, pp. 365–388, 2019.
[9] P. Sipponen and M. Kekki, “Gastric atrophy and its clinical significance,” Scandinavian Journal of Gastroenterology, vol. 28, suppl. 196, pp. 6–10, 1993.
[10] K. Sugano, J. Tack, E. J. Kuipers, et al., “Kyoto global consensus report on Helicobacter pylori gastritis,” Gut, vol. 64, no. 9, pp. 1353–1367, 2015.
[11] World Gastroenterology Organisation, Global Guidelines: Helicobacter pylori. Milwaukee, WI, USA: WGO, 2023.
[12] World Health Organization, Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2022.
[13] J. Parsonnet, G. D. Friedman, D. P. Vandersteen, et al., “Helicobacter pylori infection and the risk of gastric carcinoma,” New England Journal of Medicine, vol. 325, no. 16, pp. 1127–1131, 1991.
[14] E. M. El-Serag and H. B. Sonnenberg, “Clinical implications of Helicobacter pylori infection in chronic liver diseases,” Hepatology, vol. 39, no. 1, pp. 15–21, 2004.
[15] D. Y. Graham and Y. Yamaoka, “Helicobacter pylori and gastric carcinogenesis,” Cancer Letters, vol. 345, no. 2, pp. 148–152, 2014.
